WO2026145382 - COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COMPLEMENT FACTOR B (CFB)
National phase entry is expected:
Publication Number
WO/2026/145382
Publication Date
09.07.2026
International Application No.
PCT/CN2025/146432
International Filing Date
29.12.2025
Title **
[English]
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COMPLEMENT FACTOR B (CFB)
[French]
COMPOSITIONS ET PROCÉDÉS POUR INHIBER L'EXPRESSION DU FACTEUR B DU COMPLÉMENT (CFB)
Applicants **
SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD.
Inventors
SHU, Dongxu
SHAO, Pengcheng Patrick
Priority Data
PCT/CN2024/143605
30.12.2024
CN
PCT/CN2025/082044
12.03.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4429 | |
| EPO | Filing, Examination, Granting | 68235 | |
| Japan | Filing, Examination, Granting | 4184 | |
| South Korea | Filing, Examination, Granting | 6570 | |
| USA | Filing, Examination, Granting | 19590 |
Total:
103,008
Contact Us
Abstract[English]
Compositions and methods useful to reduce expression of CFB gene and for treatment of CFB-associated diseases and conditions are provided. Provided are CFB dsRNA agents, CFB antisense polynucleotide agents, compositions comprising CFB dsRNA agents, and compositions comprising CFB antisense polynucleotide agents that can be used to reduce CFB expression in cells and subjects.[French]
L'invention concerne des compositions et des procédés utiles pour réduire l'expression du gène CFB et pour le traitement de maladies et d'états associés à CFB. L'invention concerne des agents d'ARNdb CFB, des agents polynucléotidiques antisens CFB, des compositions comprenant des agents d'ARNdb CFB, et des compositions comprenant des agents polynucléotidiques antisens CFB qui peuvent être utilisés pour réduire l'expression de CFB dans des cellules et des sujets.